THERAPEUTIC PROCESS Sample Clauses

THERAPEUTIC PROCESS. The purpose of meeting with a therapist is to get help with problems in your life that are bothering you or that are keeping you from being successful in important areas of your life. You may be here because you wanted to talk to a therapist about these problems. Or, you may be here because your family, guardian, doctor, or teacher has concerns about you. When we meet, we will discuss these problems. I will ask questions, listen to you, and suggest a plan for improving these problems. It is important that you feel comfortable talking to me about the issues that are bothering you. Sometimes these issues will include things you don't want others to know about. For most people, knowing that what they say will be kept private helps them feel more comfortable and have more trust in their therapist. Privacy is an important and necessary part of good therapy. POSSIBLE BENEFITS AND RISKS Psychotherapy has both benefits and risks. Potential risks and unpleasant aspects may include experiencing uncomfortable levels of feelings like sadness, guilt, anxiety, anger, and frustration. It is possible that you may experience some unpleasant emotions, including uncomfortable feelings or memories, questioning of relationships, and lifestyle adjustments. You might find yourself recalling some unpleasant aspects of your history. You may find yourself questioning and reevaluating some of your most cherished beliefs and values. It is important to consider that such experiences are a normal aspect of the counseling process, and I am available to talk over with you any of these issues as they may arise. Psychotherapy has also been shown to have benefits for people who undertake it. It often leads to a reduction of feelings of distress, resolution of specific problems, and improvement in relationships with others. Of course, I cannot offer any guarantee of cure or any promise of improvement of any condition.
Sample 1
AutoNDA by SimpleDocs
THERAPEUTIC PROCESS. Interestingly, the update group had both a stronger conditioned fear response following US devaluation and reported fewer intrusions and PTSD symptoms than the exposure group. Clinical implications for this finding are tentatively suggested which include the importance of emotional arousal and reducing attentional avoidance for therapeutic change. These two processes are complementary as reduced attentional avoidance of the threat cue (CS+) would be associated with increased arousal and this combination may enable greater processing and reduced PTSD symptoms. Recovery from anxiety disorders is thought to be reliant on the person actively experiencing their anxiety whilst confronting their fear. For example, positive outcomes for PTSD are associated with the expression of fear during the first exposure session (Foa et al., 1995; Xxxxxx, Foa, & Xxxxxx, 1998), early elevations in psychophysiology during imaginal flooding predict improvements in intrusions (Xxxxxx et al., 1996) and outcomes for people with OCD are predicted by the level of anxiety activation during exposure (as measured by self-report, cardiac response and EDA) (Xxxxx, Foa, & Xxxxxxxx, 1988). Xxxx (1996) hypothesises that the presence of strong affect can make changes in cognitions more effective and durable and that cognitions are most malleable when the person is emotionally aroused (Xxxx, 1998). The combination of emotional arousal and perceptual processing during therapy has also been shown to better predict reductions in depressive and psychopathological symptoms than either alone (Xxxxxxxxxx et al., 2005). Reviews have concluded that effective therapy requires emotional engagement and arousal and that the construction of new meaning is needed for durable change (Xxxxxxxxx & Xxxxxxx-xxxxx, 2006; Xxxxxxx, 2004). Moderate emotional arousal has been shown to be optimal for therapeutic change, with the suggestion that high emotional arousal may disrupt cognitive processing and emotional regulation (Xxxxxxx & Xxxxxxxxx, 2010). Therefore, it is tentatively suggested that the updating condition may facilitate moderate emotional arousal to trauma-related cues (as indicated by SCR to the CS+USDe). Research has illustrated that aversive cues initially evoke a rapid response and then people use attentional avoidance to reduce the sense of current threat in the short term (Xxxxxx et al., 2005). Therapy (Narrative Exposure Therapy, NET) may lead to an increase in attentional allocation to potential th...
Sample 1

Related to THERAPEUTIC PROCESS

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Infusion Therapy the administration of antibiotic, nutrients, or other therapeutic agents by direct infusion. Note: The limitations on Therapy Services contained in this Therapy Services provision do not apply to any Therapy Services that are received under the Home Health Care provision or to therapy services received under the Diagnosis and Treatment of Autism or Other Developmental Disabilities provision. .

  • Annual Production Program document describing the forecasts for Production and handling of Oil, Gas, water, special fluids, and waste arising from the Production process of each Development Area or Field.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!